First Time Loading...
O

OrthoPediatrics Corp
NASDAQ:KIDS

Watchlist Manager
OrthoPediatrics Corp
NASDAQ:KIDS
Watchlist
Price: 28.97 USD 10.15% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

KIDS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. [ Read More ]

The intrinsic value of one KIDS stock under the Base Case scenario is 32.92 USD. Compared to the current market price of 28.97 USD, OrthoPediatrics Corp is Undervalued by 12%.

Key Points:
KIDS Intrinsic Value
Base Case
32.92 USD
Undervaluation 12%
Intrinsic Value
Price
O
Worst Case
Base Case
Best Case

Valuation Backtest
OrthoPediatrics Corp

Backtest KIDS Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling KIDS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Robust Q4 Earnings and Positive 2024 Outlook
2023-Q4 Earnings Call

Robust Q4 Earnings and Positive 2024 Outlook

In Q4 2023, the company's revenue soared to $37.6 million, a 21% jump from the previous year, led by strong global Trauma and Deformity sales, solid domestic Scoliosis performance, and OPSB growth. U.S. sales alone ballooned by 24%, reaching $28.3 million. Despite headwinds from soft scoliosis demand in South America, international revenue climbed 13% to $9.3 million. Set deployments maintained a robust pace with $5.9 million consigned. Gross profit margins nudged higher to 71.0% from 68.5%. Operating expenses rose by 18%, in line with business growth and elevated R&D efforts, which surged by 35%. Yet, the company achieved an adjusted EBITDA of $1.3 million, reversing a loss from the same quarter last year. Full-year guidance remains strong, predicting revenues between $197 million and $200 million, equating to a 32-34% increase, and aiming for an adjusted EBITDA from $8.0 to $9.0 million.

Financials

Balance Sheet Decomposition
OrthoPediatrics Corp

Current Assets 226.5m
Cash & Short-Term Investments 80.3m
Receivables 34.6m
Other Current Assets 111.6m
Non-Current Assets 212.2m
PP&E 41m
Intangibles 168.3m
Other Non-Current Assets 2.9m
Current Liabilities 41.7m
Accounts Payable 12.6m
Accrued Liabilities 11.3m
Other Current Liabilities 17.7m
Non-Current Liabilities 20.1m
Long-Term Debt 9.9m
Other Non-Current Liabilities 10.1m
Efficiency

Earnings Waterfall
OrthoPediatrics Corp

Revenue
148.7m USD
Cost of Revenue
-37.5m USD
Gross Profit
111.3m USD
Operating Expenses
-137m USD
Operating Income
-25.8m USD
Other Expenses
4.8m USD
Net Income
-21m USD

Free Cash Flow Analysis
OrthoPediatrics Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

KIDS Profitability Score
Profitability Due Diligence

OrthoPediatrics Corp's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROE is Increasing
Exceptional 1-Year Revenue Growth
37/100
Profitability
Score

OrthoPediatrics Corp's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

KIDS Solvency Score
Solvency Due Diligence

OrthoPediatrics Corp's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

OrthoPediatrics Corp's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KIDS Price Targets Summary
OrthoPediatrics Corp

Wall Street analysts forecast KIDS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KIDS is 40.29 USD with a low forecast of 32.32 USD and a high forecast of 52.5 USD.

Lowest
Price Target
32.32 USD
12% Upside
Average
Price Target
40.29 USD
39% Upside
Highest
Price Target
52.5 USD
81% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

KIDS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

KIDS Price
OrthoPediatrics Corp

1M 1M
+6%
6M 6M
-11%
1Y 1Y
-32%
3Y 3Y
-37%
5Y 5Y
-35%
10Y 10Y
+51%
Annual Price Range
28.97
52w Low
23.4
52w High
51.98
Price Metrics
Average Annual Return 2.62%
Standard Deviation of Annual Returns 36.23%
Max Drawdown -68%
Shares Statistics
Market Capitalization 677.3m USD
Shares Outstanding 23 550 000
Percentage of Shares Shorted 6.8%

KIDS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

OrthoPediatrics Corp

Country

United States of America

Industry

Health Care

Market Cap

677.3m USD

Dividend Yield

0%

Description

OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. The company is headquartered in Warsaw Indiana, Indiana and currently employs 133 full-time employees. The company went IPO on 2017-10-12. The firm operates through the OrthoPediatrics Segment, which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. The company offers a range of products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform Femur, Orthex, QuickPack and ApiFix Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. The company markets approximately 37 surgical systems that address pediatric trauma and deformity correction, scoliosis and sports medicine/other procedures.

Contact

INDIANA
Warsaw Indiana
2850 Frontier Dr
+15742686379.0
http://www.orthopediatrics.com/

IPO

2017-10-12

Employees

133

Officers

Executive Chairman
Mr. Mark C. Throdahl
President, CEO & Director
Mr. David R. Bailey
CFO, Principal Financial & Accounting Officer, COO and Director
Mr. Fred L. Hite
Executive VP of Legal & General Counsel
Mr. Daniel J. Gerritzen
President of Scoliosis
Mr. Gregory A. Odle
President of Enabling Technologies
Mr. Kevin L. Unger CHE, MBA/MSHA
Show More
President of Trauma & Deformity Correction
Mr. Joseph W. Hauser
Senior Vice President of Clinical & Regulatory Affairs
Mr. Joel Batts
Senior Vice President of International Sales
Mr. Mark Karshner
Show Less

See Also

Discover More
What is the Intrinsic Value of one KIDS stock?

The intrinsic value of one KIDS stock under the Base Case scenario is 32.92 USD.

Is KIDS stock undervalued or overvalued?

Compared to the current market price of 28.97 USD, OrthoPediatrics Corp is Undervalued by 12%.